JP2021510733A - がんの処置のための選択的ヒストンデアセチラーゼ3(hdac3)インヒビターと免疫治療剤との組み合わせ - Google Patents
がんの処置のための選択的ヒストンデアセチラーゼ3(hdac3)インヒビターと免疫治療剤との組み合わせ Download PDFInfo
- Publication number
- JP2021510733A JP2021510733A JP2020558865A JP2020558865A JP2021510733A JP 2021510733 A JP2021510733 A JP 2021510733A JP 2020558865 A JP2020558865 A JP 2020558865A JP 2020558865 A JP2020558865 A JP 2020558865A JP 2021510733 A JP2021510733 A JP 2021510733A
- Authority
- JP
- Japan
- Prior art keywords
- oxohexyl
- aminophenylamino
- alkyl
- rings
- carboxamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 *C(C=C1)=CCC1C(Nc(ccc(F)c1)c1N)=O Chemical compound *C(C=C1)=CCC1C(Nc(ccc(F)c1)c1N)=O 0.000 description 10
- FOQHMCZTDOIPPT-UHFFFAOYSA-N Cc(cc1)ccc1C(Nc(ccc(F)c1)c1N)=O Chemical compound Cc(cc1)ccc1C(Nc(ccc(F)c1)c1N)=O FOQHMCZTDOIPPT-UHFFFAOYSA-N 0.000 description 1
- GYQOJKRMGKKGCI-UHFFFAOYSA-N Cc1c(CC(C2)C(Nc(cccc3)c3N)=O)c2ccc1 Chemical compound Cc1c(CC(C2)C(Nc(cccc3)c3N)=O)c2ccc1 GYQOJKRMGKKGCI-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024015651A JP2024099510A (ja) | 2018-01-12 | 2024-02-05 | がんの処置のための選択的ヒストンデアセチラーゼ3(hdac3)インヒビターと免疫治療剤との組み合わせ |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862616831P | 2018-01-12 | 2018-01-12 | |
| US62/616,831 | 2018-01-12 | ||
| PCT/US2019/013375 WO2019140322A1 (en) | 2018-01-12 | 2019-01-11 | Combination of a selective histone deacetylase 3 (hdac3) inhibitor and an immunotherapy agent for the treatment of cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024015651A Division JP2024099510A (ja) | 2018-01-12 | 2024-02-05 | がんの処置のための選択的ヒストンデアセチラーゼ3(hdac3)インヒビターと免疫治療剤との組み合わせ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021510733A true JP2021510733A (ja) | 2021-04-30 |
| JP2021510733A5 JP2021510733A5 (cg-RX-API-DMAC7.html) | 2022-02-08 |
Family
ID=65516716
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020558865A Pending JP2021510733A (ja) | 2018-01-12 | 2019-01-11 | がんの処置のための選択的ヒストンデアセチラーゼ3(hdac3)インヒビターと免疫治療剤との組み合わせ |
| JP2024015651A Pending JP2024099510A (ja) | 2018-01-12 | 2024-02-05 | がんの処置のための選択的ヒストンデアセチラーゼ3(hdac3)インヒビターと免疫治療剤との組み合わせ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024015651A Pending JP2024099510A (ja) | 2018-01-12 | 2024-02-05 | がんの処置のための選択的ヒストンデアセチラーゼ3(hdac3)インヒビターと免疫治療剤との組み合わせ |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US12128018B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3737362B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2021510733A (cg-RX-API-DMAC7.html) |
| CN (1) | CN112135610A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3125731A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES3057234T3 (cg-RX-API-DMAC7.html) |
| TW (1) | TWI922427B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019140322A1 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023101505A1 (ko) * | 2021-12-03 | 2023-06-08 | 연세대학교 산학협력단 | Wnk3 억제제를 유효성분으로 포함하는 면역관문 억제용 조성물 |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012149540A1 (en) | 2011-04-28 | 2012-11-01 | The Broad Institute Inc | Inhibitors of histone deacetylase |
| EP2877444B1 (en) | 2012-07-27 | 2020-09-02 | The Broad Institute, Inc. | Inhibitors of histone deacetylase |
| CA3125731A1 (en) | 2018-01-12 | 2019-07-18 | KDAc Therapeutics, Inc. | Combination of a selective histone deacetylase 3 (hdac3) inhibitor and an immunotherapy agent for the treatment of cancer |
| MX2020010999A (es) | 2018-04-18 | 2021-01-20 | Constellation Pharmaceuticals Inc | Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos. |
| EP3797108B1 (en) | 2018-05-21 | 2022-07-20 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| PE20220562A1 (es) | 2019-07-24 | 2022-04-13 | Constellation Pharmaceuticals Inc | Formas cristalinas de 7-cloro-2-(4-(3-metoxiazetidin-1-il)ciclohexil)-2,4-dimetil-n-((6-metil-4-(metiltio)-2-oxo-1,2-dihidropiridin-3-il)metil)benzo[d][1,3]dioxol-5-carboxamida |
| WO2022251827A1 (en) * | 2021-05-24 | 2022-12-01 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Immune checkpoint inhibitor and hdac inhibitor combination therapy strategy |
| WO2023034440A1 (en) | 2021-09-01 | 2023-03-09 | Case Western Reserve University | Treatment of neurodegenerative diseases with hdac inhibitors |
| CN113754587B (zh) * | 2021-09-22 | 2023-07-14 | 沈阳药科大学 | 一种苯基吡唑类化合物及应用 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014514261A (ja) * | 2011-02-28 | 2014-06-19 | レプリジェン コーポレーション | ヒストン脱アセチル化酵素阻害剤 |
| JP2014523857A (ja) * | 2011-04-28 | 2014-09-18 | ザ ブロード インスティテュート, インコーポレイテッド | ヒストンデアセチラーゼ阻害剤 |
| JP2015528812A (ja) * | 2012-07-27 | 2015-10-01 | ザ ブロード インスティテュート, インコーポレーテッドThe Broad Institute, Inc. | ヒストンデアセチラーゼの阻害剤 |
| US20160272579A1 (en) * | 2013-11-05 | 2016-09-22 | Dana-Farber Cancer Institute, Inc. | Inhibitors of histone deacetylase |
| US9796664B2 (en) * | 2008-09-03 | 2017-10-24 | Biomarin Pharmaceutical Inc. | Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors |
Family Cites Families (117)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE670584C (de) | 1936-07-09 | 1939-01-20 | I G Farbenindustrie Akt Ges | Verfahren zur Herstellung von o-Aminophenolen |
| DE1108213B (de) | 1959-02-28 | 1961-06-08 | Frantisek Sorm Dr Ing | Verfahren zur Herstellung von 2, 2-Dimethyl-3-phenylcyclopropan-carbonsaeuren |
| SE370866B (cg-RX-API-DMAC7.html) | 1968-03-21 | 1974-11-04 | Ciba Geigy Ag | |
| JPS4825500B1 (cg-RX-API-DMAC7.html) | 1970-12-29 | 1973-07-30 | ||
| US3850931A (en) | 1971-06-25 | 1974-11-26 | American Home Prod | 4-(substituted anilino)-2-phenyl-5-pyrimidinecarboxylic acid esters |
| GB2079480B (en) | 1980-07-08 | 1984-05-16 | Kodak Ltd | Heat-activated photographic and thermal recording processes employing precursor compounds |
| NO156828C (no) | 1980-11-10 | 1987-12-02 | Otsuka Pharma Co Ltd | Analogifremgangsm te for fremstilling av antibakterielt virksomme benzoheterocykliske forbindelser. |
| JPS57102887A (en) | 1980-12-18 | 1982-06-26 | Otsuka Pharmaceut Co Ltd | Preparation of benzo(ij)quinolizine-2-carboxylic acid derivative |
| US4404356A (en) | 1981-09-09 | 1983-09-13 | Ciba-Geigy Corporation | Heat-curable epoxide resin compositions |
| JPS5853916A (ja) | 1981-09-09 | 1983-03-30 | チバ−ガイギ−・アクチエンゲゼルシヤフト | 熱硬化性エポキシド樹脂組成物 |
| US5525727A (en) | 1982-05-18 | 1996-06-11 | University Of Florida | Brain-specific drug delivery |
| DE3511110A1 (de) | 1985-03-27 | 1986-10-02 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue pyridazinone, ihre herstellung und diese verbindungen enthaltende arzneimittel |
| GB8508588D0 (en) | 1985-04-02 | 1985-05-09 | Akzo Nv | Indene & napthalene derivatives |
| NZ219974A (en) | 1986-04-22 | 1989-08-29 | Goedecke Ag | N-(2'-aminophenyl)-benzamide derivatives, process for their preparation and their use in the control of neoplastic diseases |
| IT1231413B (it) | 1987-09-23 | 1991-12-04 | Angeli Inst Spa | Derivati dell'acido benzimidazolin-2-osso-1-carbossilico utili come antagonisti dei recettori 5-ht |
| US5994392A (en) | 1988-02-26 | 1999-11-30 | Neuromedica, Inc. | Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid |
| DE3830054A1 (de) | 1988-09-03 | 1990-03-15 | Boehringer Mannheim Gmbh | Phenylamide - verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel |
| JPH03232868A (ja) | 1990-02-05 | 1991-10-16 | Nippon Telegr & Teleph Corp <Ntt> | 新規光学活性化合物及び液晶組成物 |
| US5177064A (en) | 1990-07-13 | 1993-01-05 | University Of Florida | Targeted drug delivery via phosphonate derivatives |
| JP3507486B2 (ja) | 1991-03-15 | 2004-03-15 | アムジエン・インコーポレーテツド | 顆粒球コロニー刺激因子の肺内投与 |
| JPH06122669A (ja) | 1991-12-28 | 1994-05-06 | Ishihara Sangyo Kaisha Ltd | ジアミノベンゼン誘導体を含有するホスホリパーゼa2阻害剤 |
| DE4323916A1 (de) | 1993-07-16 | 1995-01-19 | Basf Ag | Substituierte 2-Phenylpyridine |
| US5451569A (en) | 1994-04-19 | 1995-09-19 | Hong Kong University Of Science And Technology R & D Corporation Limited | Pulmonary drug delivery system |
| JPH11503110A (ja) | 1995-02-17 | 1999-03-23 | スミスクライン・ビーチャム・コーポレイション | Il−8受容体拮抗剤 |
| US5635503A (en) | 1995-06-07 | 1997-06-03 | Bristol-Myers Squibb Company | Dihydropyridine npy antagonists: piperazine derivatives |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| JPH09227495A (ja) | 1996-02-16 | 1997-09-02 | Tanabe Seiyaku Co Ltd | フェノール誘導体及びその製法 |
| EP1014962A4 (en) | 1997-06-26 | 2007-06-27 | Lilly Co Eli | ANTITHROMBOTIC AGENTS |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| JP4390024B2 (ja) | 1999-04-23 | 2009-12-24 | アステラス製薬株式会社 | 新規なジアゼパン誘導体又はその塩 |
| US6653309B1 (en) | 1999-04-26 | 2003-11-25 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme technical field of the invention |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
| US6713454B1 (en) | 1999-09-13 | 2004-03-30 | Nobex Corporation | Prodrugs of etoposide and etoposide analogs |
| AU2001233027A1 (en) | 2000-01-27 | 2001-08-07 | Genetics Institute, Llc | Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof |
| FR2805741B1 (fr) | 2000-03-06 | 2003-06-20 | Oreal | Composition de teinture d'oxydation des fibres keratiniques avec un derive particulier de la paraphenylenediamine et un colorant direct particulier |
| JP2003528074A (ja) | 2000-03-24 | 2003-09-24 | メチルジーン インコーポレイテッド | ヒストン脱アセチル化酵素の阻害剤 |
| DE10038007A1 (de) | 2000-08-04 | 2002-02-14 | Bayer Ag | Neue Amino-und Amido-Diphenylether für Arzneimittel |
| US20020173507A1 (en) | 2000-08-15 | 2002-11-21 | Vincent Santora | Urea compounds and methods of uses |
| US6645990B2 (en) | 2000-08-15 | 2003-11-11 | Amgen Inc. | Thiazolyl urea compounds and methods of uses |
| CA2417432C (en) | 2000-09-01 | 2010-11-02 | The Center For Blood Research, Inc. | Modified polypeptides stabilized in a desired conformation and methods for producing same |
| AU3950802A (en) | 2000-12-07 | 2002-06-18 | Cv Therapeutics Inc | Abca-1 elevating compounds |
| JP4183923B2 (ja) | 2001-03-29 | 2008-11-19 | 富士フイルム株式会社 | 熱現像感光材料 |
| EP1379511B1 (en) | 2001-04-12 | 2005-07-20 | F. Hoffmann-La Roche Ag | DIHYDRO-BENZO (b) (1, 4) DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II |
| AR034897A1 (es) | 2001-08-07 | 2004-03-24 | Hoffmann La Roche | Derivados n-monoacilados de o-fenilendiaminas, sus analogos heterociclicos de seis miembros y su uso como agentes farmaceuticos |
| US6949542B2 (en) | 2002-02-06 | 2005-09-27 | Hoffman-La Roche Inc. | Dihydro-benzo[b][1,4]diazepin-2-one derivatives |
| TWI319387B (en) | 2002-04-05 | 2010-01-11 | Astrazeneca Ab | Benzamide derivatives |
| NZ536420A (en) | 2002-04-12 | 2008-04-30 | Medarex Inc | Methods of treatment using CTLA-4 antibodies |
| EP1402888A1 (en) | 2002-09-18 | 2004-03-31 | Jerini AG | The use of substituted carbocyclic compounds as rotamases inhibitors |
| US7244751B2 (en) | 2003-02-14 | 2007-07-17 | Shenzhen Chipscreen Biosciences Ltd. | Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity |
| JP2006517960A (ja) | 2003-02-18 | 2006-08-03 | ファイザー インコーポレイテッド | C型肝炎ウイルスの阻害剤、それを使用する組成物および治療法 |
| WO2005025557A1 (en) | 2003-09-16 | 2005-03-24 | Monash University | An agent for plasminogen-activation and matrix metalloproteinase associated conditions and methods of use |
| AU2004276337B2 (en) | 2003-09-24 | 2009-11-12 | Methylgene Inc. | Inhibitors of histone deacetylase |
| WO2005033562A2 (en) * | 2003-10-02 | 2005-04-14 | Jesel, Inc. | Double roller cam follower |
| AU2004280264A1 (en) | 2003-10-09 | 2005-04-21 | Merck Hdac Research, Llc | Thiophene and benzothiophene hydroxamic acid derivatives |
| US20080070954A1 (en) | 2003-10-27 | 2008-03-20 | S*Bio Pte Ltd. | Acylurea Connected And Sulfonylurea Connected Hydroxamates |
| US20050137234A1 (en) | 2003-12-19 | 2005-06-23 | Syrrx, Inc. | Histone deacetylase inhibitors |
| EP1753740A2 (en) | 2004-05-21 | 2007-02-21 | Merck & Co., Inc. | Amino cyclopentyl heterocyclic and carbocyclic modulators of chemokine receptor activity |
| US20060008517A1 (en) | 2004-07-09 | 2006-01-12 | Lynch Marina A | Treatment of age-related memory impairment |
| CN101001851B (zh) | 2004-08-09 | 2011-04-20 | 安斯泰来制药有限公司 | 具有作为组蛋白脱乙酰酶(hdac)抑制剂的活性的羟基酰胺化合物 |
| JPWO2006028161A1 (ja) | 2004-09-09 | 2008-05-08 | 財団法人乙卯研究所 | セロトニン5−ht3受容体作動薬 |
| AU2006262166A1 (en) | 2005-06-24 | 2007-01-04 | Merck Sharp & Dohme Corp. | Modified malonate derivatives |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| AU2007208495A1 (en) | 2006-01-12 | 2007-08-02 | Merck Sharp & Dohme Corp. | Hydroxyalkylarylamide derivatives |
| CA2648804C (en) | 2006-04-07 | 2014-05-27 | Methylgene Inc. | Benzamide derivatives as inhibitors of histone deacetylase |
| WO2008075196A1 (en) | 2006-12-15 | 2008-06-26 | Pfizer Products Inc. | Benzimidazole derivatives |
| CA2670645A1 (en) | 2006-12-19 | 2008-07-03 | Genentech, Inc. | Pyrimidine kinase inhibitors |
| CA2673870A1 (en) | 2006-12-27 | 2008-07-10 | Emory University | Compositions and methods for the treatment of infections and tumors |
| CN103087043A (zh) | 2007-03-16 | 2013-05-08 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 具有抗增殖活性的苯甲酰胺类衍生物及其药用制剂 |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| WO2009002534A1 (en) | 2007-06-26 | 2008-12-31 | Gilead Colorado, Inc. | Imidazopyridinyl thiazolyl histone deacetylase inhibitors |
| WO2009002495A1 (en) | 2007-06-27 | 2008-12-31 | Merck & Co., Inc. | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
| US8138168B1 (en) | 2007-09-26 | 2012-03-20 | Takeda Pharmaceutical Company Limited | Renin inhibitors |
| AU2008315651B2 (en) | 2007-10-22 | 2012-12-13 | Orchid Research Laboratories Limited | Histone deacetylase inhibitors |
| BRPI0817897A2 (pt) | 2007-11-02 | 2019-09-24 | Methylgene Inc | composto, composição, e, métodos de inibição da atividade hdac, e de tratamento de uma doença responsiva a um inibidor de atividade hdac |
| WO2009076234A2 (en) | 2007-12-07 | 2009-06-18 | University Of Maryland, Baltimore | Synthesis methods of histone deacetylase inhibitors (hdacis) |
| PL2254873T3 (pl) | 2008-02-22 | 2014-10-31 | Otsuka Pharma Co Ltd | Związek benzodiazepinowy i kompozycja farmaceutyczna |
| US8093000B2 (en) * | 2008-05-09 | 2012-01-10 | The Regents Of The University Of California | Methods for predicting and treating tumors resistant to drug, immunotherapy, and radiation |
| JP5640005B2 (ja) | 2008-07-14 | 2014-12-10 | ギリアード サイエンシーズ, インコーポレイテッド | Hdacおよび/またはcdk阻害剤としてのイミダゾシルピリジン化合物 |
| WO2010014054A1 (en) | 2008-07-28 | 2010-02-04 | The Regents Of The University Of California | Inhibitors of protein prenyltransferases |
| WO2010014784A2 (en) | 2008-08-01 | 2010-02-04 | Bristol-Myers Squibb Company | Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases |
| EA201500417A1 (ru) | 2008-08-25 | 2015-11-30 | Эмплиммьюн, Инк. | Композиции антагонистов pd-1 и способы применения |
| WO2010036959A2 (en) | 2008-09-26 | 2010-04-01 | Dana-Farber Cancer Institute | Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor |
| WO2010042433A1 (en) | 2008-10-06 | 2010-04-15 | Bristol-Myers Squibb Company | Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases |
| US8232409B2 (en) | 2008-10-15 | 2012-07-31 | Janssen Pharmaceutica N.V. | Heterocyclic benzimidazoles as TRPM8 modulators |
| JP2012510512A (ja) | 2008-12-03 | 2012-05-10 | マサチューセッツ インスティテュート オブ テクノロジー | 記憶を推進するためのhdac2の阻害 |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| WO2010089411A2 (en) | 2009-02-09 | 2010-08-12 | Universite De La Mediterranee | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| WO2010094678A1 (en) | 2009-02-23 | 2010-08-26 | F. Hoffmann-La Roche Ag | Novel ortho-aminoamides for the treatment of cancer |
| WO2010135524A1 (en) | 2009-05-22 | 2010-11-25 | Exelixis, Inc. | Benzoxazepines based p13k/mt0r inhibitors against proliferative diseases |
| US8211901B2 (en) | 2009-05-22 | 2012-07-03 | Shenzhen Chipscreen Biosciences Ltd. | Naphthamide derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors |
| US8835648B2 (en) | 2009-06-11 | 2014-09-16 | Siena Biotech S.P.A. | Hedgehog pathway antagonists and therapeutic applications thereof |
| US8354419B2 (en) | 2009-07-16 | 2013-01-15 | Vertex Pharmaceuticals Incorporated | Benzimidazole analogues for the treatment or prevention of flavivirus infections |
| WO2011053876A1 (en) | 2009-10-30 | 2011-05-05 | Massachusetts Institute Of Technology | The use of ci-994 and dinaline for the treatment of memory/cognition and anxiety disorders |
| EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| WO2012112447A2 (en) | 2011-02-14 | 2012-08-23 | Dana-Farber Cancer Institute, Inc. | Histone deacetylase inhibitors and methods of use thereof |
| RU2013140975A (ru) | 2011-02-28 | 2015-04-10 | Дженентек, Инк. | Биологические маркеры и способы прогнозирования восприимчивости к антагонистам в-клеток |
| US8957066B2 (en) | 2011-02-28 | 2015-02-17 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
| CN102775356B (zh) | 2011-05-13 | 2015-07-22 | 江苏恒谊药业有限公司 | 4-氨基喹唑啉衍生物及其应用 |
| US9294896B2 (en) | 2011-07-05 | 2016-03-22 | Zia Shlaimoun | Method and system for video messaging |
| WO2013043569A1 (en) | 2011-09-20 | 2013-03-28 | Vical Incorporated | Synergistic anti-tumor efficacy using alloantigen combination immunotherapy |
| WO2013059582A2 (en) | 2011-10-20 | 2013-04-25 | Nupotential, Inc. | Small molecule inhibitors of histone deacteylases |
| WO2013067391A1 (en) | 2011-11-02 | 2013-05-10 | The Broad Institute, Inc. | Fluorescent substrates for determining lysine modifying enzyme activity |
| CA2759407A1 (en) | 2011-12-02 | 2013-06-02 | Marrett Alexander GREEN | Grey water recycling systems and valves |
| WO2013132317A1 (en) | 2012-03-07 | 2013-09-12 | Aurigene Discovery Technologies Limited | Peptidomimetic compounds as immunomodulators |
| US9856320B2 (en) | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| US9914717B2 (en) | 2012-12-20 | 2018-03-13 | The Broad Institute, Inc. | Cycloalkenyl hydroxamic acid derivatives and their use as histone deacetylase inhibitors |
| US20160346240A1 (en) | 2014-02-03 | 2016-12-01 | Quadriga Biosciences, Inc. | Methods of chemotherapy using chemotherapeutic agents based on beta-substituted beta-amino acids and analogs |
| JP2017508798A (ja) | 2014-03-07 | 2017-03-30 | ザ ジョンズ ホプキンス ユニバーシティ | ヒストンリジン特異的デメチラーゼ(lsd1)およびヒストンデアセチラーゼ(hdac)の阻害剤 |
| SG11201702401RA (en) | 2014-10-14 | 2017-04-27 | Novartis Ag | Antibody molecules to pd-l1 and uses thereof |
| GB201514756D0 (en) * | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compound and method of use |
| TWI794171B (zh) * | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Hdac抑制劑與pd-l1抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| WO2018132391A1 (en) | 2017-01-10 | 2018-07-19 | Dana-Farber Cancer Institute, Inc. | Compositions and methods using an epigenetic inhibitor |
| CA3125731A1 (en) | 2018-01-12 | 2019-07-18 | KDAc Therapeutics, Inc. | Combination of a selective histone deacetylase 3 (hdac3) inhibitor and an immunotherapy agent for the treatment of cancer |
-
2019
- 2019-01-11 CA CA3125731A patent/CA3125731A1/en active Pending
- 2019-01-11 WO PCT/US2019/013375 patent/WO2019140322A1/en not_active Ceased
- 2019-01-11 JP JP2020558865A patent/JP2021510733A/ja active Pending
- 2019-01-11 US US16/246,320 patent/US12128018B2/en active Active
- 2019-01-11 ES ES19706776T patent/ES3057234T3/es active Active
- 2019-01-11 CN CN201980018750.2A patent/CN112135610A/zh active Pending
- 2019-01-11 EP EP19706776.2A patent/EP3737362B1/en active Active
- 2019-01-14 TW TW108101414A patent/TWI922427B/zh active
-
2024
- 2024-02-05 JP JP2024015651A patent/JP2024099510A/ja active Pending
- 2024-09-19 US US18/890,566 patent/US20250255839A1/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9796664B2 (en) * | 2008-09-03 | 2017-10-24 | Biomarin Pharmaceutical Inc. | Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors |
| JP2014514261A (ja) * | 2011-02-28 | 2014-06-19 | レプリジェン コーポレーション | ヒストン脱アセチル化酵素阻害剤 |
| JP2014523857A (ja) * | 2011-04-28 | 2014-09-18 | ザ ブロード インスティテュート, インコーポレイテッド | ヒストンデアセチラーゼ阻害剤 |
| JP2015528812A (ja) * | 2012-07-27 | 2015-10-01 | ザ ブロード インスティテュート, インコーポレーテッドThe Broad Institute, Inc. | ヒストンデアセチラーゼの阻害剤 |
| US20160272579A1 (en) * | 2013-11-05 | 2016-09-22 | Dana-Farber Cancer Institute, Inc. | Inhibitors of histone deacetylase |
Non-Patent Citations (2)
| Title |
|---|
| MOLECULAR IMMUNOLOGY, vol. 87, JPN6023005553, 2017, pages 227 - 239, ISSN: 0005295033 * |
| PP.E854-E855, THE JOURNAL OF UROLOGY, vol. 197, JPN6023005555, 2017, pages 65 - 07, ISSN: 0005295032 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023101505A1 (ko) * | 2021-12-03 | 2023-06-08 | 연세대학교 산학협력단 | Wnk3 억제제를 유효성분으로 포함하는 면역관문 억제용 조성물 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20190216754A1 (en) | 2019-07-18 |
| US20210177781A9 (en) | 2021-06-17 |
| CA3125731A1 (en) | 2019-07-18 |
| WO2019140322A1 (en) | 2019-07-18 |
| EP3737362B1 (en) | 2025-10-15 |
| CN112135610A (zh) | 2020-12-25 |
| TW201938149A (zh) | 2019-10-01 |
| ES3057234T3 (en) | 2026-02-27 |
| US20250255839A1 (en) | 2025-08-14 |
| JP2024099510A (ja) | 2024-07-25 |
| TWI922427B (zh) | 2026-04-21 |
| US12128018B2 (en) | 2024-10-29 |
| EP3737362A1 (en) | 2020-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250255839A1 (en) | Combination of a selective histone deacetylase 3 (hdac3) inhibitor and an immunotherapy agent for the treatment of cancer | |
| CN113993519B (zh) | 细胞周期蛋白依赖性激酶12(cdk12)的降解剂及其用途 | |
| JP7643874B2 (ja) | がん幹細胞を標的化するがん治療 | |
| EP3876939A1 (en) | Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof | |
| AU2015360416A1 (en) | Fused 1,3-azole derivatives useful for the treatment of proliferative diseases | |
| US12109207B2 (en) | Methods of using 4(1H)-quinolone derivatives | |
| US10865213B2 (en) | Max binders as MYC modulators and uses thereof | |
| JP7821573B2 (ja) | Dot1lディグレーダーおよびその使用 | |
| JP2021514955A (ja) | プロテアソーム関連ユビキチン受容体rpn13機能を阻止する低分子およびその使用法 | |
| JP2022516745A (ja) | Dot1l分解剤およびその使用 | |
| AU2019318046B2 (en) | Histone demethylase 5 inhibitors and uses thereof | |
| US20230339865A1 (en) | Quinazoline-derived hck inhibitors for use in the treatment of myd88 mutated diseases | |
| HK40041778A (en) | Combination of a selective histone deacetylase 3 (hdac3) inhibitor and an immunotherapy agent for the treatment of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220111 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220111 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220126 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20220126 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230213 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230310 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20231005 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240205 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20240207 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20240301 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20240405 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260406 |